Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by stock analysts at Cowen and Company in a report issued on Friday, July 14th. They presently have a $190.00 price objective on the specialty pharmaceutical company’s stock. Cowen and Company’s price objective indicates a potential upside of 33.14% from the company’s current price.
Other equities research analysts also recently issued research reports about the stock. TheStreet raised shares of Jazz Pharmaceuticals PLC from a “c+” rating to a “b-” rating in a report on Tuesday, March 28th. Janney Montgomery Scott raised shares of Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $138.00 to $175.00 in a report on Thursday, April 6th. Vetr downgraded shares of Jazz Pharmaceuticals PLC from a “strong-buy” rating to a “buy” rating and set a $161.19 price objective for the company. in a report on Monday, March 27th. Mizuho reaffirmed a “buy” rating and issued a $162.00 price objective (up previously from $152.00) on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, March 21st. Finally, Deutsche Bank AG set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Thursday, April 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $182.72.
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.66% during mid-day trading on Friday, reaching $142.71. 476,916 shares of the company were exchanged. The firm has a market capitalization of $8.57 billion, a price-to-earnings ratio of 21.98 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The company’s 50-day moving average is $154.90 and its 200 day moving average is $146.69.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same period last year, the firm posted $2.67 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. Analysts predict that Jazz Pharmaceuticals PLC will post $10.87 EPS for the current year.
WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/13/cowen-and-company-reaffirms-buy-rating-for-jazz-pharmaceuticals-plc-nasdaqjazz-updated-updated-updated.html.
In other news, Director Rick E. Winningham sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $150.00, for a total value of $750,000.00. Following the transaction, the director now owns 10,391 shares in the company, valued at approximately $1,558,650. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the completion of the transaction, the executive vice president now owns 32,322 shares in the company, valued at approximately $5,171,520. The disclosure for this sale can be found here. Insiders sold a total of 10,600 shares of company stock worth $1,641,720 in the last quarter. 4.30% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after buying an additional 153,908 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares during the last quarter. Janus Capital Management LLC boosted its stake in shares of Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after buying an additional 468,940 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Jazz Pharmaceuticals PLC by 3.2% in the first quarter. Bank of New York Mellon Corp now owns 1,447,760 shares of the specialty pharmaceutical company’s stock valued at $210,114,000 after buying an additional 44,973 shares during the last quarter. Institutional investors own 86.43% of the company’s stock.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.
